2013 - Pharmacy Technician Pulse

Study finds hepatitis C cure saved Medicaid $15 billion

PhRMA

JANUARY 5, 2023

The study finds that since curative direct-acting antiviral medications for hepatitis C were approved in 2013, even after factoring in the cost of treatment, Medicaid has saved an estimated $15 billion in avoided health care costs and nearly 285,000 Medicaid enrollees are estimated to have been cured.

Pumping breastmilk in bathrooms is a common, albeit unspoken, practice at health care conferences

STAT

JANUARY 18, 2024

This was back in 2013, when such accommodations were a rarity. Even though Erin Booth was not thrilled about having to travel to Philadelphia for a conference at six weeks postpartum, this one at least advertised having a private lactation space.

Q&A: The scientific integrity sleuth taking on the widespread problem of research misconduct

STAT

FEBRUARY 28, 2024

Bik first became interested in plagiarism as a hobby while working as a researcher at Stanford University in 2013. She later began specializing in image duplication specifically, which she believes is a more serious problem for science as a whole. Read the rest…

STAT+: Goldman Sachs launches $650 million fund for life science investments

STAT

JANUARY 3, 2024

billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 Around $25.6 billion had been raised by 556 first-time funds in 2022.

'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study

Fierce Pharma

APRIL 8, 2024

Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found. One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials.

FDA

Study points to weaknesses in FDA accelerated approval path

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

FDA

Medicare Part D Claims Have Increased, But 340B Prescriptions Increased Faster

Pharmacy Times

DECEMBER 4, 2023

in 2013 to 19.3% The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% to 49.9%.

Prescription Filling

Opinion: To overcome the overdose crisis, addiction treatment must be integrated into the health care system

STAT

JULY 19, 2024

The first time I saw Maya (not her real name) huddled under blankets in a hospital bed in 2013, she had been to dozens of inpatient detox programs and residential treatment centers since she had begun using heroin two decades earlier. After every release, she returned to heroin use, usually within days.

Hospitals

STAT+: Payments by drug and device makers to doctors remain widespread, but also vary considerably

STAT

MARCH 28, 2024

From 2013 to 2022, pharmaceutical and device companies made more than 85 million payments totaling $12.1 The financial ties between drug and device makers and some physicians remains pervasive, despite concerns such relationships may influence medical practice, according to a new analysis of payments made over a recent 10-year span.

STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira

STAT

FEBRUARY 20, 2024

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July.

STAT+: AI drug firm Recursion moves from survival to industry domination

STAT

AUGUST 19, 2024

The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased cells, and use that data to identify drugs gathering dust on pharmaceutical company shelves that could be repurposed as rare disease treatments.

Medical Schools

Medical Schools Pharmaceutical Companies Pharmaceutical Companies

STAT+: A flurry of research misconduct cases has universities scrambling to protect themselves

STAT

FEBRUARY 12, 2024

Over the past decade, the number of research misconduct allegations reported to the National Institutes of Health has more than doubled, climbing from 74 in 2013 to 169 in 2022. And it’s hardly alone. And scientific sleuths are finding plenty of other problems that don’t always qualify as outright misconduct.

Health tech company Commure to acquire Augmedix in $139M deal as AI scribe competition heats up

Fierce Healthcare

JULY 19, 2024

Healthcare technology company Commure plans to buy Augmedix, a healthcare artificial intelligence company founded in 2013, the companies announced Friday. | On Friday, ambient AI documentation company Augmedix announced it had been bought by Commure, a large IT vendor to healthcare systems. The deal values the company at $139 million.

Documentation

STAT+: CRISPR’s pioneers reflect on the first gene-editing treatment

STAT

NOVEMBER 18, 2023

It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists , published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9.

STAT+: Life sciences deals on track to hit lowest point since 2017

STAT

OCTOBER 11, 2023

So far this year, there have been 1,384 VC deals struck in the field, the lowest figure since 2013. New data from Pitchbook and the National Venture Capital Association show that both the number of deals and the amount of money that’s being invested in life science companies are down significantly.

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

STAT

DECEMBER 8, 2023

Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame with the same goal of turning the nascent CRISPR gene-editing technology into medicines.

STAT+: About half of cancer drugs given accelerated approval don’t improve survival or quality of life

STAT

APRIL 7, 2024

In 2013, it took an average of 9.9 In some cases, failure to show clinical benefit didn’t stop the FDA from converting accelerated approvals into full approvals, and the authors note the agency’s conversion decisions have increasingly been based on less stringent evidence of a drug’s benefits.

FDA

Roche looks to grow Gazyva's reach with phase 3 lupus nephritis win

Fierce Pharma

SEPTEMBER 26, 2024

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis. |

STAT+: Pear Therapeutics sold for parts at $6 million auction

STAT

MAY 19, 2023

Founded in 2013, Pear was the most prominent company developing prescription digital therapeutics, or Food and Drug Administration-cleared software applications ordered by doctors to treat health conditions. Click Therapeutics, Welt Corp, Harvest Bio, and Nox Health Group each acquired bits of the company for $6.05

FDA

2024 BCPS Exam – What’s Changing?

Med Ed 101

OCTOBER 4, 2023

It’s hard to believe that I have been following pharmacist board certifications and helping pharmacists pass the BCPS exam for over 10 years since I first passed it in 2013! Each year in updating and creating our study materials, I review the content outline and any possible changes in the BCPS exam.

HPV Vaccination Rates Could Improve With Increased Reimbursement

Drug Topics

JULY 28, 2023

of women aged 18-59 in 2013-2014. According to the CDC, HPV is the most commonly sexually transmitted infection in the US, with a prevalence of 45.2% of men and 39.9%

Vaccines

Opinion: How I fought Big Pharma on insulin prices — and won

STAT

SEPTEMBER 20, 2024

In 2013, I sat down at my computer and secured the URL t1international.com. I wanted a place where I could collect and share everything I was learning about the global insulin price crisis. I was only 25 years old, and I had already been living with type 1 diabetes for more than two decades.

Hospitals

STAT+: Endo Health ordered to pay more than $1.5 billion in opioid criminal case

STAT

MAY 7, 2024

The company, which last month pleaded guilty to a misdemeanor, admitted that, from April 2012 through May 2013, some of its sales representatives marketed its medicine, also known as oxymorphone, to doctors by touting the drug as abuse deterrent, as well as resistant to tampering and crushing.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

STAT+: Jeff Jonas leaves Sage Therapeutics to launch biotech incubator

STAT

NOVEMBER 10, 2022

He has been part of the C-suite at Sage Therapeutics since 2013. Longtime Sage Therapeutics executive Jeff Jonas is leaving the biotech company to launch a biotech incubator with global investment giant CBC Group. Sage announced this week that Jonas would leave the company to join a private equity firm. billion deal with Biogen.

AbbVie announces its new CEO

European Pharmaceutical Review

FEBRUARY 23, 2024

Richard Gonzalez will retire as the company’s CEO to become Executive Chairman, having served as the company’s CEO since its launch in 2013, AbbVie noted. Richard has facilitated AbbVie securing a market capitalisation increase from $54 billion in 2013 to over $300 billion in 2024.

Hospitals

STAT+: Drug industry payments to eye docs boosted Medicare spending on pricier treatments

STAT

SEPTEMBER 28, 2023

million from 2013 to 2019, presumably due to the company payments, according to the study, which was published in JAMA Health Forum. Physicians who did not accept payments prescribed Avastin 46% of the time, nearly twice as often as those who accepted payments. As a result, Medicare shelled out an estimated $642.8

Insurance

Opinion: Bashing accelerated approval isn’t supported by the data

STAT

APRIL 23, 2024

Case in point: Under the seemingly benign title, “Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval,” an article published recently in the Journal of the American Medical Association claims that among “cancer drugs granted accelerated approval from 2013 to 2017, 41% (19/46) did not improve (..)

FDA

Diabetes treatments are improving. Racial disparities are wider than ever

STAT

DECEMBER 20, 2022

For example, the share of Mexican Americans taking insulin who achieved good blood-sugar control sharply dropped to 10% during the period of 2013 to 2020 from 25% during 1988 to 1994, researchers reported Tuesday in JAMA Network Open. Read the rest…

Mallinckrodt pays $260m to settle kickback, rebate fraud charges

pharmaphorum

MARCH 10, 2022

It says the price increases were imposed “as though a new version of Acthar came on the market in 2013, when in fact, it did not,” which allowed it to ignore all price increases prior to 2013 in its rebate calculations.

Opinion: The decline and fall of elite multispecialty medical groups

STAT

JANUARY 17, 2024

Central Texas’ Scott and White was absorbed into Baylor in 2013. Wisconsin’s Marshfield Clinic agreed to merge with Duluth-based Essentia Health in October 2022 after a lengthy string of operating losses, though the merger fell apart recently.

Hospitals

STAT+: Former Sage executives join biotech VC Cure Ventures

STAT

JANUARY 8, 2024

The two men worked together from 2013 until 2022, when Jonas left to start a biotech incubator with funding from investment giant CBC Group. The VC firm has hired Jeff Jonas, Sage’s former chief executive, and Al Robichaud, Sage’s former chief scientific officer, as partners, the team told STAT exclusively.

Labelling

Labelling FDA

How does HTA for orphan drugs differ across Europe?

pharmaphorum

AUGUST 4, 2020

The study reviewed all 80 European Medicines Agency (EMA) authorised drugs receiving an orphan designation between 1 January 2013 and 31 December 2019, analysing their HTA outcomes and time to reimbursement across France, Germany, England and Scotland. Rates of approval. A more favourable outcome from the German regulator took on average 1.4

Labelling

STAT+: Carbon Health blasts a major insurer in rare public dispute over coverage

STAT

MAY 1, 2023

San Francisco-based Carbon said that Elevance — formerly known as Anthem, which operates the Anthem Blue Cross plan in California — had refused to increase its payment rate in the state beyond 2013 levels, which was “no longer tenable as a livable wage.” ” Continue to STAT+ to read the full story…

Insurance

STAT+: FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients

STAT

OCTOBER 12, 2022

A federal law that went into effect in 2013 requires the FDA to identify ingredients needed to satisfy an unmet “clinical need” and to include those on a list for use by large compounding pharmacies.

Compounding Pharmacies

Compounding Pharmacies Compounding FDA

STAT+: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia

STAT

DECEMBER 13, 2022

When it hit the market in 2013, the drug revolutionized the treatment of these cancers and represented a major step forward from chemotherapy and some other drugs at the time. NEW ORLEANS – One of the best therapies for some types of lymphoma and leukemia has been a drug called ibrutinib, made by AbbVie.

Chemotherapy

Peculiar Articles: 10 Potential Conversation Starters From The Medical Literature

IDStewardship

DECEMBER 15, 2024

Public perception of pharmacists: Film and television portrayals from 1970 to 2013. For example, “Aztreoman – aztreonam by day, aztreoman by night” and “Caspafungin – the friendly ghost.” Were James Bond’s drinks shaken because of alcohol induced tremor? What is the public perception of pharmacists?

Opinion: Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails

STAT

MARCH 9, 2023

In the spring of 2013, I had just visited a lab focused on gene and cell therapies at Baylor College of Medicine. Bluebird Bio , which would soon launch a successful IPO , had licensed its technology from the same lab and was about to announce a major collaboration with Celgene and Baylor.

Merck takes Keytruda patent dispute with Johns Hopkins University from the court to the patent office

Fierce Pharma

MARCH 13, 2024

The company in 2022 claimed the research university breached its contracts relating to a joint trial the two ran in 2013 and wrongly secured patents for itself from the study. Patent and Trademark Office (PTO) to weigh in following a 2022 complaint. | Now, Merck is taking its complaints to the patent office.

STAT+: Feds accuse CVS of filling ‘thousands’ of illicit opioid prescriptions

STAT

DECEMBER 19, 2024

The lawsuit alleged that, since October 2013, CVS knowingly filled prescriptions for “dangerous and excessive quantities” of controlled substances that lacked a legitimate medical purpose, were not valid, and were not issued in the “usual course of professional practice. Department of Justice.

Controlled Substances

Controlled Substances Insurance

STAT+: Freespira bets on slow and steady, amid spectacular digital health collapses

STAT

JUNE 18, 2024

based company was founded in 2013 and has raised $60 million to date. Perekupka said Freespira hopes to enroll 2,500 people in its treatment this year — twice last year’s sales — and to double its patients again in 2025 and 2026. The Kirkland, Wash.-based

Insurance

Viagra May Alleviate Dysmenorrhea-Related Pain, However Funding Challenges Have Limited Clinical Research

Pharmacy Times

MARCH 11, 2024

The early phase clinical trial, which ended prematurely in 2013 due to funding challenges, further illustrates disparities in health equity in clinical research.

Opinion: Compounding pharmacies offer a fix for shortages of essential drugs

STAT

MAY 15, 2023

Hospitals ran short of essential treatment medications and were unable to source those drugs from manufacturers or from the outsourcing facilities that had been authorized by Congress in 2013 to “fill the gap” in such situations.

Compounding Pharmacies

Compounding Pharmacies Compounding Hospitals FDA

STAT+: Former Magellan Diagnostics execs charged with selling defective lead testing machines used for kids

STAT

APRIL 5, 2023

are charged with knowingly selling defective lead testing machines between 2013 and 2017 that generated inaccurate results for tens of thousands of children across the country and for clients of at least one international relief organization, federal prosecutors said. Three former executives at Magellan Diagnostics Inc.

Supply chain middlemen ‘pocket half of US branded medicine spending’

pharmaphorum

JANUARY 13, 2022

The report from Berkeley Research Group (BRG) – which was funded by the pharma industry trade group PhRMA – reveals a steady decrease in the proportion received by drugmakers from around 67% in 2013 to 49.5%

Payment Processing

Payment Processing Generic Medicine Insurance Hospitals

Study finds hepatitis C cure saved Medicaid $15 billion

Pumping breastmilk in bathrooms is a common, albeit unspoken, practice at health care conferences

Trending Sources

Q&A: The scientific integrity sleuth taking on the widespread problem of research misconduct

STAT+: Goldman Sachs launches $650 million fund for life science investments

'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study

Study points to weaknesses in FDA accelerated approval path

Medicare Part D Claims Have Increased, But 340B Prescriptions Increased Faster

Opinion: To overcome the overdose crisis, addiction treatment must be integrated into the health care system

STAT+: Payments by drug and device makers to doctors remain widespread, but also vary considerably

STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira

STAT+: AI drug firm Recursion moves from survival to industry domination

STAT+: A flurry of research misconduct cases has universities scrambling to protect themselves

Health tech company Commure to acquire Augmedix in $139M deal as AI scribe competition heats up

STAT+: CRISPR’s pioneers reflect on the first gene-editing treatment

STAT+: Life sciences deals on track to hit lowest point since 2017

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

STAT+: About half of cancer drugs given accelerated approval don’t improve survival or quality of life

Roche looks to grow Gazyva's reach with phase 3 lupus nephritis win

STAT+: Pear Therapeutics sold for parts at $6 million auction

2024 BCPS Exam – What’s Changing?

HPV Vaccination Rates Could Improve With Increased Reimbursement

Opinion: How I fought Big Pharma on insulin prices — and won

STAT+: Endo Health ordered to pay more than $1.5 billion in opioid criminal case

STAT+: Jeff Jonas leaves Sage Therapeutics to launch biotech incubator

AbbVie announces its new CEO

STAT+: Drug industry payments to eye docs boosted Medicare spending on pricier treatments

Opinion: Bashing accelerated approval isn’t supported by the data

Diabetes treatments are improving. Racial disparities are wider than ever

Mallinckrodt pays $260m to settle kickback, rebate fraud charges

Opinion: The decline and fall of elite multispecialty medical groups

STAT+: Former Sage executives join biotech VC Cure Ventures

How does HTA for orphan drugs differ across Europe?

STAT+: Carbon Health blasts a major insurer in rare public dispute over coverage

STAT+: FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients

STAT+: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia

Peculiar Articles: 10 Potential Conversation Starters From The Medical Literature

Opinion: Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails

Merck takes Keytruda patent dispute with Johns Hopkins University from the court to the patent office

STAT+: Feds accuse CVS of filling ‘thousands’ of illicit opioid prescriptions

STAT+: Freespira bets on slow and steady, amid spectacular digital health collapses

Viagra May Alleviate Dysmenorrhea-Related Pain, However Funding Challenges Have Limited Clinical Research

Opinion: Compounding pharmacies offer a fix for shortages of essential drugs

STAT+: Former Magellan Diagnostics execs charged with selling defective lead testing machines used for kids

Supply chain middlemen ‘pocket half of US branded medicine spending’

Stay Connected